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A B S T R A C T
Background
Corticosteroid treatment is considered the ’gold standard’ for Duchenne muscular dystrophy (DMD); however, it is also known to
induce osteoporosis and thus increase the risk of vertebral fragility fractures. Good practice in the care of those with DMD requires
prevention of these adverse effects. Treatments to increase bone mineral density include bisphosphonates and vitamin D and calcium
supplements, and in adolescents with pubertal delay, testosterone. Bone health management is an important part of lifelong care for
patients with DMD.
Objectives
To assess the effects of interventions to prevent or treat osteoporosis in children and adults with DMD taking long-term corticosteroids;
to assess the effects of these interventions on the frequency of vertebral fragility fractures and long-bone fractures, and on quality of
life; and to assess adverse events.
Search methods
On 12 September 2016, we searched the Cochrane Neuromuscular Specialised Register, CENTRAL, MEDLINE, Embase, and
CINAHL Plus to identify potentially eligible trials. We also searched theWeb of Science ISI Proceedings (2001 to September 2016) and
three clinical trials registries to identify unpublished studies and ongoing trials. We contacted correspondence authors of the included
studies in the review to obtain information on unpublished studies or work in progress.
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Selection criteria
We considered for inclusion in the review randomised controlled trials (RCTs) and quasi-RCTs involving any bone health intervention
for corticosteroid-induced osteoporosis and fragility fractures in children, adolescents, and adults with a confirmed diagnosis of DMD.
The interventions might have included oral and intravenous bisphosphonates, vitamin D supplements, calcium supplements, dietary
calcium, testosterone, and weight-bearing activity.
Data collection and analysis
Two review authors independently assessed reports and selected potential studies for inclusion, following standard Cochrane method-
ology. We contacted study authors to obtain further information for clarification on published work, unpublished studies, and work
in progress.
Main results
We identified 18 potential studies, of which two, currently reported only as abstracts, met the inclusion criteria for this review. Too little
information was available for us to present full results or adequately assess risk of bias. The participants were children aged five to 15
years with DMD, ambulant and non-ambulant. The interventions were risedronate versus no treatment in one trial (13 participants)
and whole-body vibration versus a placebo device in the second (21 participants). Both studies reported improved bone mineral density
with the active treatments, with no improvement in the control groups, but the abstracts did not compare treatment and control
conditions. All children tolerated whole-body vibration treatment. No study provided information on adverse events. Two studies are
ongoing: one investigating whole-body vibration, the other investigating zoledronic acid.
Authors’ conclusions
We know of no high-quality evidence from RCTs to guide use of treatments to prevent or treat corticosteroid-induced osteoporosis
and reduce the risk of fragility fractures in children and adults with DMD; only limited results from two trials reported in abstracts
were available. We await formal trial reports. Findings from two ongoing relevant studies and two trials, for which only abstracts are
available, will be important in future updates of this review.
P L A I N L A N G U A G E S U M M A R Y
Treatments to prevent and treat thinning of bones and prevent fractures caused by corticosteroids in Duchenne muscular
dystrophy
Review question
What are the effects of treatments to prevent or treat thinning of bones (osteoporosis) and prevent fragile bones from breaking (fragility
fractures) in adults and children with Duchenne muscular dystrophy (DMD) who are taking long-term corticosteroids?
Background
DMD is an inherited condition, affecting about one in 3500 to one in 6000 newborn boys. DMD causes muscle weakness that becomes
more severe with age. Muscle weakness is widespread, affecting movement, the digestive system, breathing, and the heart. The pattern
of weakness mainly affects muscles near the trunk, around the shoulders, and at the hips. If untreated, DMD leads to death in the late
teens from breathing or heart complications. A child with DMD often shows the first signs of this disease before starting school. If
untreated, he will lose the ability to walk by the age of 13 years and need to use a wheelchair. There is no cure for DMD, but medicines
called corticosteroids slow muscle damage and enable boys with DMD to walk for longer. Boys with DMD also tend to have weak
bones because of their weak muscles and reduced mobility.
Corticosteroids cause osteoporosis (thinning of the bones), which makes the bones more fragile and liable to fracture (break). Therapies,
such as vitamin D and calcium supplements, more calcium in the diet, medicines called bisphosphonates, testosterone, and weight-
bearing exercise, might be able to strengthen bone to prevent and treat osteoporosis and prevent fractures in people with DMD who
are taking corticosteroids. Investigators use bone density as a measure of how strong the bone is and to measure the effects of therapies
to prevent and treat osteoporosis.
Study characteristics
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We searched the medical literature comprehensively, finding two completed trials. Only brief reports (abstracts) of these trials are
available. The participants were children aged from five to 15 years with DMD who were able to walk and not able to walk. The
treatments were risedronate versus no treatment in one trial (with 13 participants) and whole-body vibration versus a placebo (inactive)
device in the other (with 21 participants).
Key results and quality of the evidence
We found two completed studies that were potentially eligible for this review, for which full results have not yet been published, and
two studies ongoing at the time of the search. These studies are looking at the effects of whole-body vibration (two studies), risedronate,
and zoledronic acid. Both completed trials, presented as abstracts only, reported an improvement in bone mineral density in children
who received active treatment and no improvement in children in the control (placebo or no treatment) groups. However, the reports
did not report results for the comparison of treatment versus control groups, which means that it is not possible to draw conclusions
about the effectiveness of either treatment. All children tolerated whole-body vibration treatment. Neither study provided information
on adverse events.
We know of no evidence from randomised clinical trials to guide use of treatments to prevent or treat osteoporosis and prevent fragility
fractures in people with DMD taking corticosteroids.
Searches are current to September 2016.
B A C K G R O U N D
Description of the condition
Duchenne muscular dystrophy (DMD)
Duchenne muscular dystrophy (DMD) is a progressive disorder
affecting skeletal, cardiac, and smoothmuscle (Emery1998;Voisin
2004). Inheritance is sex-linked recessive, and the condition has an
incidence of one in 3500 to one in 6000 male live births (Emery
1991; Emery 2003; Flanigan 2012). DMD is caused by deletions,
duplications or mutations in the dystrophin gene located at Xp21,
resulting in the absence or low levels of the protein known as dys-
trophin (Chaturvedi 2001; Flanigan 2009; Lee 2012; Muntoni
2003; Soltanzadeh 2010). Dystrophin is a large protein located
on the sarcolemmal membrane. It forms part of the dystrophin-
associated protein complex and is involved in membrane integrity.
Absence of dystrophin leads to membrane damage and progressive
dystrophic changes within the muscle (Blake 2002; Deconinck
2007). Affected boys appear normal at birth and first show signs
of muscle weakness in early childhood, often as a toddler. With-
out treatment, they become wheelchair dependent by 13 years of
age. Without respiratory support, death occurs in the late teens or
early twenties. Because of postural imbalance and reduced mus-
cular support to the spine, scoliosis (spinal deformity) typically
develops. Scoliosis of the thoracic region restricts movement of the
ribs making breathing even more difficult for already weakened
respiratory muscles. However, in recent years, prognosis has im-
proved substantially with the introduction of non-invasive ventila-
tion support along with cough-assist technology and co-ordinated
multidisciplinary care (Bushby 2010; Passamano 2012).
Corticosteroid treatment is now considered the ’gold standard’
for DMD, and corticosteroid-induced osteoporosis is an impor-
tant emerging problem (Bushby 2010). Corticosteroids have been
shown to slow the decline inmuscle function and may protect car-
diac and respiratory function. Corticosteroid-treated boys lose the
ability towalk at around12 to 14 years of age, comparedwith seven
to 13 years for non-treated boys (Matthews 2010; Ricotti 2012).
Physicians usually start treatment during the ’plateau phase’ of
the condition (usually between four and six years of age) (Bushby
2010).Doses of prednisone, prednisolone, or deflazacort are either
taken daily, Biggar 2004; Fenichel 1991; Griggs 1991; Matthews
2010;Mesa 1991, or intermittently, Dubowitz 2002; Kinali 2002.
Treatment that is continued after the loss of ambulation may pre-
serve upper body strength, respiratory and cardiac function, and
delay the onset of scoliosis (Balaban 2005; Biggar 2004; Biggar
2006; Daftary 2007; Hussein 2014; King 2007; Lebel 2013;
Manzur 2008; Schram 2013). Corticosteroids have significant
side-effects, which require proactive management (Angelini 2007;
Balaban 2005; Biggar 2006; Bonifati 2000; Bushby 2004; Bushby
2010; Houde 2008; King 2007; Manzur 2008; Matthews 2010;
Merlini 2012; Moxley 2010). One such side-effect is corticos-
teroid-induced osteoporosis, which includes the increased risk of
vertebral fractures (Angelini 2012; Bachrach 2005; Balaban 2005;
Bothwell 2003; Bianchi 2003; Canalis 2004; Houde 2008; King
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2007; Mayo 2012; Quinlivan 2010; Soderpalm 2007; Van Staa
2003; Weldon 2009).
Osteoporosis
Osteoporosis is a progressive, systemic skeletal disease, charac-
terised by reduced bone mass and micro-architectural deteriora-
tion of bone tissue. As a result, bone is increasingly fragile and
more susceptible to fracture (NICE 2012). Fragility fractures are
fractures that result from mechanical forces that would not ordi-
narily result in fracture. Osteoporotic fragility fractures are defined
as fractures associated with low bone mineral density and include
spine, forearm, hip, and shoulder fractures.
In children and adolescents, osteoporosis is defined as low bone
mineral content or bone mineral density for chronological age.
The diagnosis of osteoporosis requires the presence of both a clin-
ically significant fracture history, for example, vertebral compres-
sion fracture or long-bone fractures, and low bone mineral con-
tent or bone mineral density. Low bone mineral content or bone
mineral density is defined as bones with a Z-score that is less than
or equal to -2.0, adjusted for age, gender, and body size, as appro-
priate (ISCD 2007).
Bone mineral content and bone mineral density are assessed in
children by dual-energy X-ray absorptiometry (DXA) (Bianchi
2010). Quantitative-computed tomography, peripheral quantita-
tive-computed tomography, quantitative ultrasonography, ormag-
netic resonance imaging (MRI) are also used (Bachrach 2011;
Buckner 2015). To avoid incorrect estimations, conventionalDXA
measurements are adjusted according to size for use in chil-
dren, those with deteriorating bone, and people of shorter stature
(Bianchi 2014). Bone mineral density is measured as age-based
andheight-adjustedZ-scores (Bachrach 2011; Baim2008; Bianchi
2010; Crabtree 2014; Fewtrell 2003). DXA can also predict the
risk of fractures before they occur. Its use is based on a relationship
between low bone mineral density and risk of fracture in adults,
which also exists in children (Clark 2006; Goulding 1998). This is
an important application of DXA in patients with DMD, as part
of bone health evaluation (Bianchi 2011a).
Bone is a living tissue, which bone formation and bone resorp-
tion constantly remodels (Joyce 2012). Factors that affect bone
health include genetics, nutrition, physical activity (loading), age,
and hormones. Corticosteroid treatment affects endocrine func-
tion, suppressing growth, delaying puberty, reducing bone min-
eral density, and increasing body weight (Bianchi 2011a; Dooley
2013; Wood 2015). Corticosteroids induce bone loss by hinder-
ing bone formation through osteoblastic apoptosis (the death of
cells that make bone) and by stimulating bone mineral resorption
through an increase in the number of osteoclasts (cells that break
down bone) (Popp 2006). The reduction in bone mineral density
from changes in bone metabolism is not fully understood (Bianchi
2011a). Deficiencies in testosterone (delayed puberty) and growth
hormone, or resistance to an insulin-like growth hormone, and
limited mobility with excessive weight gain contribute to a reduc-
tion in bone mineral density (Allen 1998; Bianchi 2011a; Dooley
2013). Bone mineral density is difficult to assess in DMD due
to lack of normative curves, short stature, delayed bone age, etc.
Corticosteroid treatment may not appear to reduce bone mineral
density to the same extent as in adults. Soderpalm 2008 com-
mented that lower bone mineral density in boys with DMD is
likely to be the combined result of corticosteroid treatment, mus-
cle loss from the disease, and reduced mobility. Low bone min-
eral density increases the risk of bone fragility fractures (Bachrach
2005; Douvillez 2005; Joyce 2012; Quinlivan 2005; Talim 2002).
There are some data to suggest that boys with DMD who are
corticosteroid-naive (that is, those who have not previously been
exposed to corticosteroids) are at increased risk of long-bone frac-
tures (Biggar 2006;Granata 1991;Houde 2008;Hsu 1979; Larson
2000; McDonald 2002; Vestergaard 2001), implying that corti-
costeroids are not the only cause for these fractures and causation
is complex.
Osteoporotic fragility fractures
Vertebral fragility fractures are recognised as the most common
manifestation of corticosteroid-induced osteoporosis (Al-Osail
2010; Rodd 2012; Sugiyama 2011; Van Staa 2000; Van Staa
2001; Van Staa 2003; Varonos 1987). Vertebral fragility fractures
have not been reported in corticosteroid-naive patients withDMD
of any age (Alman 2004; Houde 2008; King 2007), and very
often, vertebral fractures are not tracked in children with DMD
(especially those not treated with steroids). In boys with DMD
taking corticosteroids, the occurrence of vertebral fractures ranges
from 15% to 75% after a mean duration of 6.3 years on treatment
(ranging from 4.5 to 8.0 years) (Bothwell 2003; Houde 2008;
King 2007; Mayo 2012). The incidence of long-bone fractures
was, however, similar in treated and untreated patients (Houde
2008; McDonald 2002) (24% and 26%, respectively, in Houde
2008).
Those treated with corticosteroids tend to be more ambulant, and
patients who are more ambulant are more likely to fall and sustain
a long-bone fracture. Non-ambulatory patients appear to be at an
increased risk of vertebral fractures (Larson 2000; Mayo 2012).
Previous surgical intervention for scoliosis may also prevent verte-
bral fragility fractures (Mayo 2012). Lack of ambulation, taking
steroids previously, or both, may lead to a greater body fat com-
position in patients with DMD. Body fat percentage was reported
as significantly higher in patients with vertebral fractures (47.8%
± 12%) than in those with long-bone fractures (33% ± 14.2%) (P
< 0.05) (Mayo 2012).
Vertebral fractures can be symptomatic or asymptomatic. Acute
back pain is closely associated with symptomatic vertebral fragility
fractures (odds ratio (OR) 10.6, 95% confidence interval (CI)
2.1 to 53.8, P = 0.004) and requires radiological investigation
to confirm the diagnosis (Huber 2010; Talim 2002), but an es-
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timated 20% of vertebral fractures are asymptomatic (Manzur
2010). Asymptomatic fractures are thought to be precursors of
painful symptomatic fragility fractures (Leung 2011). Asymp-
tomatic fracturesmay be undetected because radiological or densit-
ometric monitoring is not conducted routinely (Quinlivan 2010).
Diagnosis and confirmation of a vertebral fracture requires visual
examinationof lateral X-ray ormagnetic resonance imaging (MRI)
images to assess the change in shape of the vertebrae as biconcave,
wedge, or crush, as well as the degree of deformity (Genant 1993;
Lenchik 2004; Quinlivan 2010).
The occurrence of fractures is significantly related to low bone
mineral density in DMD (Aparicio 2002; Khatri 2008; Larson
2000). Bone mineral density is often lower than normal for the
age of the patient (Bianchi 2003; Crabtree 2010; Mayo 2012;
Soderpalm 2012). In children and adolescents with DMD, the
baseline bone mineral density is low due to lack of weight-bearing
activity. It is probably lowered further by corticosteroids. While
some studies have shown no reduction in spinal bone mineral
density after 30 months of corticosteroid therapy for DMD in
prepubertal boys (Crabtree 2010), or only a marginal reduction
in children and adolescents taking corticosteroids (Cohran 2008),
others reported a substantially lowered bone mineral density in
boys (children and adolescents) taking corticosteroids, particularly
those with reduced mobility (Bianchi 2003; Hawker 2005; Mayo
2012).
International consensus workshops have taken place to prioritise
poor bone health in DMD patients and to improve clinical out-
comes through education (Biggar 2005; Leung 2011; Muntoni
2006;Quinlivan2005;Quinlivan 2010). Recent advances in treat-
ments for muscle loss have enabled people with DMD to actively
participate in life for longer. Bone health in patients with DMD
is an important issue because long-bone fractures seriously harm
mobility: approximately 20% to 50% of independently mobile
patients lose the ability to walk unaided following a long-bone
fracture (Larson 2000; Manzur 2010; Mayo 2012; McDonald
2002; Vestergaard 2001). Identifying treatment strategies to pre-
vent corticosteroid-induced osteoporosis andprevent oftenpainful
fragility fractures in DMD may have a significant effect in im-
proving quality of life for these patients.
Description of the intervention
The following pharmacological and non-pharmacological inter-
ventions are thought to have the potential to prevent or treat cor-
ticosteroid-induced osteoporosis by increasing bone mineral den-
sity and reduce the risk of fractures in patients with DMD.
Bisphosphonates
Intravenous bisphosphonates are used to treat painful vertebral
fractures in boys with DMD and are associated with improve-
ments in back pain (Sbrocchi 2012). The use of bisphosphonate
treatment in children is relatively new, but there are growing num-
bers of trials suggesting benefit, particularly in children with os-
teogenesis imperfecta (bone fragility) (Allington 2005; Bianchi
2000; Brumsen 1997; Glorieux 1998; Hawker 2005; Henderson
2002; Houston 2014; Palomo 2011; Plotkin 2000; Plotkin 2006;
Rauch 2002; Rudge 2005; Sbrocchi 2012; Shaw 2000; Sholas
2005; Wagner 2011; Ward 2011). A randomised controlled trial
(RCT) to investigate the efficacy and safety of daily oral alen-
dronate in children and adolescents with osteogenesis imperfecta
over two years found that the mean spine area Z-score increased
from -4.6 to -3.3 compared to -4.6 to -4.5 in the placebo group.
Long-bone fracture incidence and bone pain were similar between
groups (Ward 2011).
Bisphosphonates appear to be well tolerated by children for peri-
ods of up to three years (Shaw2005;Ward 2007b).Dosing regimes
differ among paediatric studies (Ward 2007b). Oral bisphospho-
nates are prescribed according to body weight (mg/kg) (Bianchi
2000; Hawker 2005; Rudge 2005). Intravenous bisphosphonates
are usually administered at a dose of 1 mg/kg to 1.5 mg/kg (Acott
2005; Shaw 2000).
Treatment is usually combined with vitamin D and calcium sup-
plements to minimise the risk of hypocalcaemia (Maalouf 2006;
Poole 2012); however, calcium supplements reduce the absorption
of bisphosphonates. Adverse effects are more common with intra-
venous than oral bisphosphonates (Somalo 2007). The U.S. Food
and Drug Adminstration (FDA) is reviewing long-term use (FDA
2011). Atypical fractures occurring with prolonged bisphospho-
nate therapy have been a featured concern in recent publications
(Compston 2011; Edwards 2010; Girgis 2010; Isaacs 2010; Shane
2010), and there have been cautions that high and prolonged doses
may paradoxically induce osteoporosis (Whyte 2008).
Calcium
Abalanced calcium-rich diet is recommended as the best long-term
strategy to maintain adequate calcium levels (Bacciottini 2004;
Biggar 2005; Sunyecz 2008). Calcium supplements in healthy
children have shown short-term improvements in bone mineral
density (Winzenberg 2006). Intestinal calcium absorption is de-
pendent on other factors such as vitamin D levels.
Genetics determine 60% to 80% of attained peak bone mass, and
environmental factors, such as nutrition, exercise, and disease, de-
termine the remainder (Quinlivan 2010). Bone mineral density
can vary between individuals from early childhood and be predic-
tive of a potential fracture risk in children with medical conditions
affecting bone health (Ferrari 1998;Goulding 2005;Harvey 2012;
Quinlivan 2010; Winzenberg 2006). A review of calcium supple-
mentation for improving bone mineral density in children showed
no effect on spinal bone mineral density, but a small effect on total
body bonemineral content (BMC) (Winzenberg 2006). A double-
blind, placebo-controlled study of 149 girls showed an increase in
bone mineral density in those taking calcium-supplemented food
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compared to those who did not (Bonjour 1997). There is poor
evidence to indicate whether calcium supplementation alone re-
duces the risk of fractures (Black 2002; Bolland 2015; Goulding
1998; Goulding 2004; Petridou 1997; Winzenberg 2006). The
consumption of adequate dietary calcium and vitamin D can in-
crease bonemineral density in patientswithDMD(Bianchi 2011).
Evidence that calcium alone has a positive effect on bone health
in boys with DMD is limited.
Vitamin D
Significantly lower serum 25OHD levels have been highlighted
in boys with DMD, especially in those taking corticosteroids
(Bianchi 2003; Bianchi 2011). People taking corticosteroids are
twice as likely to have low 25OHD levels as those not on corticos-
teroids (OR2.36, 95%CI 1.25 to 4.45) (Skversky 2011).Dhawan
2010 proposed that corticosteroids may inactivate 25OHD by in-
creasing the activity of the enzyme 24-hydroxylase.
Vitamin D levels collected in boys with DMD aged from 1.5 to
15.5 years prior to starting corticosteroid treatment revealed that
78% had inadequate levels and 15% qualified as deficient (Munot
2010). In two other studies, 54% to 70% of those with DMD
on corticosteroids were vitamin D deficient (Manzur 2010; Wong
2010).
In aCochraneReview, the bonemineral density in healthy children
taking vitamin D supplements did not change, but bone mineral
density did increase in those with low 25OHD levels (Winzenberg
2010). When investigators examined vitamin D levels at the time
of a vertebral fracture in boys with DMD, they categorised the
mean serum vitamin D levels as insufficient (Manzur 2010).
Testosterone
Testosterone is the primary sex hormone for the maturation of sex
characteristics in adolescentmales. It is also involved in the increase
in muscle strength and bone mineral content during puberty (
Seeman 2001; Wood 2015). Testosterone is a steroid hormone
produced by the testes and the adrenal glands and belongs to a
group of male hormones known as androgens. The production
of this hormone is regulated by the hypothalamus and pituitary
gland.
Long-term corticosteroid treatment in prepubertal boys can slow
down growth and delay puberty compared to their healthy peers
(Wood 2015). All but one of 44 boys with DMD aged 13 years
and upwards assessed at Cincinnati Children’s Hospital were pre-
pubertal, compared to the 50% of healthy UK boys who are in
puberty by 12 years of age (Bianchi 2011a; Bonifati 2000). Al-
though not clearly understood, high doses of corticosteroids in-
hibit or reduce the secretion of gonadotrophin-releasing hormone
by the hypothalamus, which in turn down-regulates pituitary go-
nadotrophin production. Corticosteroids may also have a direct
effect on the testes to reduce testosterone production. A deficiency
in testosterone can delay the onset of puberty (Al-Harbi 2008;
Eastell 1998; Hampson 2002; Kamischke 1998a; Reid 1985).
The absence or delay of puberty has a significant adverse effect on
bone health, which is already poor in those with DMD due to cor-
ticosteroid treatment, diminishing muscle mass, and reduced mo-
bility (Bianchi 2011a; Fairfield 2001; Guzman 2012; Reid 1985).
Hypogonadism increases the risk of osteoporosis and fractures.
Testosterone is an important hormone involved in the develop-
ment of bone and in the maintenance of bone mineral density
in adolescence and adulthood (Amory 2004; Devogelaer 1992;
Katznelson 1996; Kenny 2001; Leder 2002; Tenover 1992).
Weight-bearing exercise
In DMD patients over eight years of age, there is a gradual decline
in physical activity due to natural disease progression (Mazzone
2011; McDonald 2010). Weight-bearing exercise, for example,
walking, stimulates bone regeneration. Dynamic-loading activity
achieves greater gains in bone tissue than static activity (Lanyon
1984). Muscle weakness hinders dynamic weight-bearing exercise
and has a negative impact on bone development. Disuse of the
skeleton as a result of prolonged inactivity degenerates bone tissue
further.
How the intervention might work
In children with corticosteroid-induced osteoporosis, the rate of
bone resorption exceeds that of bone formation. The main focus
of interventions is either to slow bone resorption or promote bone
formation to increase bone mineral density whilst receiving cor-
ticosteroid therapy. These interventions can be used alone or in
combination to prevent or treat bone loss.
Bisphosphonates
Bisphosphonates are drugs that inhibit bone resorption by caus-
ing apoptosis of osteoclasts (Fleisch 2003; Poole 2012; Rogers
2011; Russell 2008). They are inorganic analogues of naturally
occurring pyrophosphates, which prevent calcification by bind-
ing to hydroxyapatite salt in bone (Nancollas 2006; Russell 2011;
Sebestyen 2012). Bisphosphonates accumulate at bone resorp-
tion sites in the skeleton and stop osteoclast-mediated activity
(Dominguez 2011; Drake 2008; Fleisch 2003; Hughes 1989;
Hughes 1995; Sato 1991; Sebestyen 2012; Somalo 2007). There
are two groups of bisphosphonates: non-nitrogen-containing bis-
phosphonates (etidronate, clodronate, and tiludronate) and nitro-
gen-containing bisphosphonates (alendronate, risedronate, iban-
dronate, pamidronate, and zoledronate). The presence of a ni-
trogen or amino group in the chemical structure of bisphospho-
nates increases the potency of the drugs for osteoclastic activ-
ity (Drake 2008; Ebetino 2011; Reszka 2004). These more po-
tent nitrogen-containing bisphosphonates are often used to treat
6Interventions to prevent and treat corticosteroid-induced osteoporosis and prevent osteoporotic fractures in Duchenne muscular
dystrophy (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
children with corticosteroid-induced osteoporosis and osteopenia
(Allington 2005; Black 2012; Brumsen 1997;Hawker 2005; Poole
2012; Rudge 2005; Schwartz 2010; Sholas 2005).
Calcium
Calcium is essential to enable normal bone growth and develop-
ment in children and adolescents (Flynn 2003; Peacock 2010).
When combined with phosphate, calcium has a structural role in
bone health as a component of bone matrix hydroxyapatite, which
provides compressional strength in bone (Bonjour 2011; Peacock
2010).During remodelling, bone turns over calcium.Remodelling
activity determines the amount of calcium required to maintain
bone health, and this varies throughout life (Mesias 2011). Cal-
cium requirements are greater during adolescence as growth peaks,
and approximately 40% of total skeletal bone mass is acquired
(Flynn 2003; Greer 2006; Mesias 2011; Weaver 2006). Calcium
deficiency can contribute to the development of osteoporosis. Not
only is there inadequate calcium for bone mineralisation, but bone
calcium stores are deleted to maintain blood calcium levels. Re-
duced blood calcium levels triggers parathyroid hormone (PTH)
release (Peacock 2010). PTH stimulates osteoclasts and bone re-
sorption. High blood calcium levels result in calcitonin release,
which inhibits osteoclast activity, promoting bone formation and
storage of excess calcium in the bone matrix.
The relationship between calcium intake and bone mass is compli-
cated in DMD patients because corticosteroid treatment induces
bone resorption, transferring calcium from bone to blood. High
blood calcium levels prevent further intestinal calcium absorption
to build bone. However, adequate calcium intake could slow bone
resorption and contribute to improving bone health in boys and
adolescents with DMD (Bianchi 2011; Quinlivan 2010). Many
intervention studies inDMDpatients have advised a daily calcium
supplement of 750 mg (Hawker 2005; Mayo 2012).
Vitamin D
Vitamin D is vital for intestinal calcium absorption (Frolik 1971;
Wei 2010). It may also have its own protective effect on bone
(Bartoszewska 2010; Peppone 2010). Vitamin D (ergocalcif-
erol) is largely man-made and present in supplemented food. The
skin synthesises vitamin D (cholecalciferol) after exposure to
sunlight, and it is also available in the diet (Misra 2008). The
liver metabolises vitamin D into calcifediol (25-dihydroxyvitamin
D (25OHD)), which the kidneys convert to the active calcitriol
(1,25-dihydroxyvitamin D ) (Peppone 2010). Vitamin D defi-
ciency can cause rickets in children and osteomalacia in adults
from poor bone mineralisation (Holick 2007; Pela 2012; Misra
2008; Wagner 2008; Ward 2007a). To a lesser extent, vitamin D
deficiency contributes to bone resorption and osteoporosis (Joyce
2012; Lips 2006). Many children and young adults in the UK
have vitamin D insufficiency from increased use of sunscreens and
reduced outdoor activities (Biggar 2005; Davies 2011; Lips 2012;
Misra 2008; Pela 2012). Its prevalence, especially in non-white
families, is underappreciated (Ahmed 2011; Kehler 2013; Lips
2010; Shaw 2011; Zipitis 2006).
Calcitriol slows bone resorption and enhances bonemineralisation
because it aids calcium absorption. Calcitriol influences the genes
that control neuromuscular cell proliferation, differentiation, and
apoptosis (Banerjee 2003; Carlberg 2003; Garcia 2011). There is
little evidence that increasing vitamin D intake alone reduces the
risk of fractures (Bischoff-Ferrari 2005; DIPART 2010; Looker
2008).
Testosterone
Testosterone therapy increases trabecular bone density (Katznelson
1996). Testosterone is used to reverse delayed puberty, reduced
growth, and osteoporosis exacerbated by corticosteroid use in
DMD (Bianchi 2011a).
Testosterone replacement therapy is started in low doses at around
14 years of age and increased over three to four years until adult
levels are reached. The expected benefits include an increase in
bone density, muscle strength, and energy levels from a pubertal
growth spurt.
Testosterone supplementation can also increase height and im-
prove quality of life during adolescence and young adulthood from
an improved body image (Landon 1984; Mason 2011). A meta-
analysis of eight RCTs examining the use of testosterone in 365
men found moderate gains in lumbar bone density (Tracz 2006).
Three of the eight studies included men taking corticosteroids (N
= 87). The meta-analysis concluded that the effect of testosterone
was weak with regard to osteoporosis prevention and treatment
in men, as no bone fracture data were available. Another review
of RCTs for the effects of testosterone on body composition in
middle-aged men found that testosterone improved bone mineral
density at the lumbar spine by 3.7% (CI 1.0% to 6.4%) compared
to placebo (Isidori 2005).
Weight-bearing exercise
The most evident decline in vertebral bone mineral density in
DMD appears to occur with the loss of independent ambulation,
regardless of whether or not the patient is taking corticosteroids
(Biggar 2004; Crabtree 2010; Mayo 2012). A reduction in me-
chanical loading reduces osteoblast bone formation and promotes
osteoclast-mediated bone resorption (Takata 2001). A study re-
vealed that bone mineral density at a number of sites including
the lumbar spine improved with calcium and exercise in prepu-
bertal and early pubertal boys (Bass 2007; Iuliano-Burns 2003;
Stear 2003). The IowaBoneDevelopment Study found significant
longitudinal associations between physical activity that increased
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the mechanical loading of the skeleton in boys aged five years and
bone mineral content of the hip at eight and 11 years of age (Janz
2010). Growing bone adapts to withstand mechanical loading. In
boys with DMD, standing programs and prolongation of walk-
ing using mechanical walking aids are common components of
management (Pedlow 2015), and boys have shown improvement
in vertebral bone mineral density and function capacity (Bianchi
2013; Spencer 1962).More recently, high-frequency, low-intensity
whole-body vibration appeared to improve bone health in children
and adolescents with a disability (Matute-Llorente 2015; Reyes
2011; Ruck 2010), but was inconclusive in people with DMD
(Söderpalm 2013). Regular low-intensity and appropriate exercise
strengthens bone tissue, as well as improving the balance of action
between opposing muscle groups and balance while standing and
moving (Bushby 2010; Grange 2007; Jansen 2010). These inter-
ventions could reduce the risk of fractures in non-ambulant boys
(Ward 2004).
Why it is important to do this review
Corticosteroids delay the loss of ambulation and cardiorespiratory
failure in patients with DMD. However, boys require treatment
for many years, and the risk of vertebral fragility and possibly long-
bone fractures is high. Identifying treatment strategies to prevent
and treat osteoporosis and prevent fragility fractures will improve
the quality of life for these patients.
O B J E C T I V E S
Toassess the effects of interventions to delay or treat osteoporosis in
children and adults with DMD taking long-term corticosteroids;
to assess the effects of these interventions on the frequency of
vertebral fragility fractures and long-bone fractures, and on quality
of life; and to assess adverse events.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We searched for all randomised controlled trials (RCTs) and
quasi-RCTs involving treatment or prevention of corticosteroid-
induced osteoporosis and prevention of fragility fractures in pa-
tients with DMD who were taking corticosteroids. Quasi-RCTs
employ methods of allocation that are not truly randomised (for
example, by alternation or using date of birth or hospital number).
Types of participants
We considered for inclusion in the review all children, adolescents,
and adults with a diagnosis of DMD, with any pathogenic mu-
tation, deletion, or duplication confirmed by genetic testing or
muscle biopsy showing the complete absence of dystrophin.
Types of interventions
We considered for inclusion in the review any intervention to
prevent or treat corticosteroid-induced osteoporosis or prevent
fragility fractures in patients with DMD compared with placebo,
another intervention, or no treatment (no available standard care).
The interventions included oral and intravenous bisphosphonates
(including both non-amino and amino groups), vitamin D sup-
plements, calcium supplements, dietary calcium, testosterone, and
weight-bearing activity.
We planned to analyse oral and intravenous bisphosphonates sep-
arately.
Types of outcome measures
Primary outcomes
1. Change in vertebral bone mineral density measured by
dual-energy X-ray absorptiometry (DXA) and expressed as a Z-
score (which is based on age-matched results with a correction for
body height) between baseline and 24 months of intervention.
The presence of vertebral compression fractures could artificially
increase bone mineral density and produce higher Z-scores in an
individual. However, we considered this effect unlikely to influ-
ence the outcome of a meta-analysis.
Secondary outcomes
Secondary outcomes measured between baseline and 24 months
of intervention.
1. The number of vertebral fragility fractures, defined as one
or a combination of the following: end-plate deformity with a
reduction in the mid-vertebral height (biconcavity), decrease in
the anterior vertebral height (wedging), or reduction in the
anterior and posterior vertebral height (compression or crush).
Identification of such vertebral fractures was based on visual
evaluation with an assessment of grade or severity linked to
vertebral height, shape, and appearance (Baim 2008), for
example, using the Genant visual semi-quantitative method
(Genant 1993). Fractures were detected using lateral spinal X-
ray, DXA vertebral fracture assessment (VFA), computed-
tomography (CT) scans, or magnetic resonance imaging (MRI).
2. The number of long-bone fractures.
3. Change in reported bone pain measured using a
standardised pain score (McGrath 2008), such as the visual
analogue scale (VAS) (Scott 1979; Zebracki 2008).
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4. Change in quality of life, measured using a validated rating
scale, for example, the Pediatric Quality of Life Inventory
(PedsQL) (Varni 2001), Neuromuscular Module and Generic
Core Scales (Davis 2010).
5. Any adverse events; adverse events that led to the
withdrawal of treatment; serious adverse events that are fatal,
life-threatening, or led to prolonged hospitalisation; and specific
adverse events, such as jaw osteonecrosis and atypical femur
fractures.
Search methods for identification of studies
Electronic searches
On 12 September 2016, we searched the following databases to
identify potentially eligible trials:
• the Cochrane Neuromuscular Specialised Register;
• CENTRAL (the Cochrane Central Register of Controlled
Trials) in the Cochrane Register of Studies Online;
• MEDLINE OvidSP (1966 to September 2016);
• Embase OvidSP (1980 to September 2016);
• CINAHL (Cumulative Index to Nursing and Allied Health
Literature) Plus (1982 to September 2016); and
• Web of Science Core Collection (Proceedings paper or
Meeting abstract) (2001 to September 2016).
We did not limit our search by language or publication status.
The detailed search strategies are in the appendices.
• Cochrane Neuromuscular Specialised Register (Appendix 1)
• CENTRAL (Appendix 2)
• MEDLINE (Appendix 3)
• Embase (Appendix 4)
• CINAHL Plus (Appendix 5)
• WOS (Appendix 6)
Searching other resources
In addition, we searched the following registries to identify un-
published data, unpublished studies, and ongoing trials:
• US National Institutes of Health Ongoing Trials Register
ClinicalTrials.gov (www.clinicaltrials.gov; searched 11 October
2011);
• the World Health Organization International Clinical Trials
Registry Platform (ICTRP, apps.who.int/trialsearch; searched 11
October 2011); and
• the ISRCTN registry (www.isrctn.com; searched 11
October 2011).
We presented detailed search strategies in the appendices.
• ClinicalTrials.gov (Appendix 7)
• ICTRP (Appendix 8)
• ISRCTN registry (Appendix 9)
Data collection and analysis
Selection of studies
Two review authors (JMB and MS) independently reviewed ti-
tles and abstracts from the electronic search results and selected
papers for full-text review according to the inclusion criteria. We
obtained the full text of all potentially relevant studies for further
assessment and selected studies that met the inclusion criteria. We
would have resolved disagreements by discussion, but there were
no disagreements. We agreed by discussion to contact five study
authors to obtain further information for clarification on pub-
lished work, unpublished studies, and work in progress.
We collated multiple reports of the same study under the same
study ID.We completed a PRISMA flow diagram, ’Characteristics
of excluded studies’ tables, and ’Characteristics of ongoing studies’
tables to detail the selection process.
A lack of randomised trials, other than two abstracts, meant that
the two review authors (JMB andMS) were unable to extract data.
Assessment of risk of bias in included studies
Two review authors (JMB and MS) independently assessed the
risk of bias in the included studies, and a third (BB) verified the
assessments. We used the domain-based evaluation described in
the Cochrane Handbook for Systematic Reviews of Interventions (
Higgins 2011a). The domains included the following:
1. random sequence generation;
2. allocation concealment;
3. blinding of participants and personnel;
4. blinding of outcome assessors;
5. incomplete outcome data;
6. selective reporting; and
7. other bias.
For each domain, we graded the risk of bias as high, low, or unclear
(Higgins 2011a). We contacted the trial’s corresponding authors
for clarification of insufficient detail in study reports. We resolved
disagreements through discussion with the other review authors,
and we assigned studies to the following categories.
• Low risk of bias: all domains at low risk of bias.
• High risk of bias: two or more domains at high risk of bias.
• Unclear risk of bias: one or more domains at unclear risk of
bias.
We constructed a ’Risk of bias’ table using RevMan to present the
results. When considering treatment effects, we planned to take
into account the risk of bias in the studies that contributed to the
outcome.
We would have used the ’Risk of bias’ assessments to perform
sensitivity analyses, if sufficient data had been available.
Information on risk of bias related to unpublished data or corre-
spondence with a trialist was noted in the ’Risk of bias’ table.
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Assesment of bias in conducting the systematic
review
We conducted the review according to the published protocol (Bell
2014). We would have reported any deviations from protocol in
Differences between protocol and review.
Appendix 10 details methods described in the protocol to be fol-
lowed if data become available for analysis in future.
Data synthesis
In the absence of meta-analysis or full-text trial reports, we pre-
sented the limited data available narratively, in the Results section.
R E S U L T S
Description of studies
Results of the search
The total number of potentially relevant references retrieved from
each database was 645: 58 from the Cochrane Neuromuscular
Specialised Register, 78 from the Cochrane Central Register of
Controlled Trials (CENTRAL), 303 from MEDLINE, 159 from
Embase, 22 from CINAHL (Cumulative Index to Nursing and
Allied Health Literature) Plus, and 25 from Web of Science ISI
Proceedings. The number of references from database searches
after deduplication was 506.
We identified 30 additional references from other sources: four
from the US National Institutes of Health Ongoing Trials Regis-
ter ClinicalTrials.gov (www.clinicaltrials.gov), seven from the IS-
RCTN registry, 17 from ICTRP, one published study from cor-
respondence with a co-author (AH), and one unpublished study
from correspondence with an author of related studies. The num-
ber of studies from these sources after deduplication was 26.
The number of references selected for further review based on their
titles and abstracts was 18. Of these, only two met the inclusion
criteria for the review, but only conference abstracts were available.
We requested unpublished data from the authors of both studies;
one responded with further information, and the second did not
respond. We categorised two further studies as Ongoing studies.
We illustrated the overall study selection process in a flow diagram
(Figure 1).
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Figure 1. A flow diagram illustrating the study selection process.
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Included studies
We found two randomised clinical trials that appeared relevant for
inclusion in this review (see Characteristics of included studies).
McSweeney 2014 assessed the effects of bisphosphonate therapy
(risedronate 1 mg/kg, maximum 35 mg) combined with calcium
(500 mg/day) and vitamin D (10 mg/day) compared to calcium
and vitamin D alone in a randomised controlled trial (RCT) in-
volving 13 boys withDuchenne muscular dystrophy (DMD). The
median age of participants was 8.5 years (range 5.4 to 15.5 years);
nine boys were ambulant and on corticosteroid therapy. The ab-
stract did not provide information on funding sources.
Bianchi 2013 investigatedweight-bearing activity (low-magnitude
high-frequency vibration) compared to the effects of a placebo
device on bone mineral density in 21 ambulant boys who had
received corticosteroids for at least six months. The trial had
a prospective, double-blind, randomised, placebo-controlled de-
sign. The abstract did not provide information on funding sources.
Both studies were reported in conference abstracts, but there was
insufficient information available to collect outcome data or as-
sess risk of bias. We contacted both primary authors for further
information: Bianchi 2013 had no further information to offer
until publication, and we received no response from McSweeney
2014. We do not have information on when we can expect full
publication of the results.
Excluded studies
We excluded 14 studies that did not meet the inclusion criteria
for this review (see Characteristics of excluded studies). The rea-
sons for rejection were that the studies did not include patients
with DMD in the study population (Adachi 2001; Cohran 2013),
were not randomised (Bianchi 2011; Biggar 2004; Cohran 2008,
Hawker 2005; Houston 2014; Mayo 2012; Srinivasan 2016;
Sbrocchi 2012; Söderpalm 2013), or did not assess the effects of
the intervention on bone health (Dubowitz 1984; Scott 1981;
Yilmaz 2004).
Ongoing studies
We found two ongoing clinical studies (see Characteristics of
ongoing studies). The first was a RCT to assess the effect of a
novel whole-body vibration therapy on bone health as well as
muscle strength (NCT01954940). This trial was registered on
13 September 2013, with an estimated recruitment end date in
March 2015. The study is still recruiting participants (last verified
26 July 2016). The second was a RCT of zoledronic acid (Aclasta)
versus vitamin D plus calcium in children and adolescents with
DMD, to assess change in lumbar spine bone density over 12
months (ACTRN12610000507088). The trial was registered on
18 June 2010, and the anticipated date of the enrollment of the
last participant is 31 December 2016.
Risk of bias in included studies
See Characteristics of included studies and Figure 1 and Figure 2
for ’Risk of bias’ assessments. As information was only available
from abstracts, we were limited in our ability to fully assess risk of
bias. We assessed random sequence generation as low risk for both
studies (Bianchi 2013;McSweeney 2014) and blinding as low risk
for (Bianchi 2013). We assessed all other domains as unclear.
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Figure 2. ’Risk of bias’ summary: review authors’ judgements about each ’Risk of bias’ item for each
included study. Green = low risk of bias; yellow = unclear risk of bias; red (not shown) = high risk of bias.
Effects of interventions
Risedronate, calcium, and vitamin D versus calcium
and vitamin D alone
Studied in McSweeney 2014
McSweeney 2014 (N = 13) randomised participants with a spine
Z-score less than -1.0 to risedronate plus calcium and vitamin D
(N = 6) or to calcium and vitamin D alone (N = 7). At baseline
and 12 months, investigators measured the spine and whole body
bone mineral density Z-score in both groups (Table 1). The study
authors reported a significant improvement in bone mineral den-
sity of the spine and whole body at 12 months compared to base-
line in the risedronate group. The published abstract reported no
information on fractures. Nine participants were ambulant and
taking corticosteroid therapy, but it is unclear whether those tak-
ing risdronate were ambulant. If current practice was applied, all
participants given risdronate would be taking corticosteroids. The
abstract did not provide information on adverse events.
Weight-bearing activity (low-magnitude high-
frequency vibration) versus placebo device
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Studied in Bianchi 2013
Bianchi 2013 examined the benefits of low-magnitude high-fre-
quency vibration by randomising 21 ambulant children with
DMD taking corticosteroids (mean age 9.3 ± 3.9 years) to either
vibration devices (N = 11) or placebo devices (N = 10). Spine,
hip, and whole-body bone mineral density measurements were
taken at baseline, six, and 12 months to monitor change in each
treatment group. Bone mineral density significantly increased at
12 months versus baseline in the active group only (spine bone
mineral apparent density (BMAD): +7.9%, P < 0.02; total body
(TB): +6.8%, P < 0.02; femoral neck: +9.8%, P < 0.01). There was
“no change or a decrease” in bone mineral density versus baseline
in the placebo group (spine BMAD: -2.9%; TB: -3.9%; femoral
neck: -4.8%). All children tolerated whole-body vibration treat-
ment. The abstract provided no information on fractures.
D I S C U S S I O N
Summary of main results
This review was only able to include two randomised studies in-
volving a total of 34 boys with Duchenne muscular dystrophy
(DMD) (Bianchi 2013; McSweeney 2014). One study compared
risedronate plus calcium and vitamin D with calcium and vitamin
D alone; the other compared the effects of whole-body vibration
with a placebo intervention. Neither study was published except
in abstract form. Although each trial reported improvements in
bone mineral density with active treatment over baseline, the ab-
stracts provide insufficient data for analysis or to assess the quality
of the evidence.
Evidence from non-randomised studies
In the absence of data from studies meeting the inclusion criteria
for this review, we detailed results of non-randomised studies to
inform future trial design and provide a platform for new RCTs of
needed interventions to improve or stabilise bone health in DMD.
Bisphosphonates
NoRCTs of alendronate in boys withDMDhave been conducted.
A small retrospective study assessed the effects of alendronate in 29
participants with DMD with a mean age of 12 years (23/29 par-
ticipants had been treated with corticosteroids) (Houston 2014).
Nineteen boys had dual-energy X-ray absorptiometry (DXA)mea-
surements taken during alendronate treatment over a mean of 3.7
years. This study reported a non-significant effect in favour of alen-
dronate on lumbar spine bone mineral density Z-score (Houston
2014). The lumbar spine bone mineral density Z-score increased
from -2.09 to -1.65 (P = 0.38). In comparison, seven participants
not taking alendronate but taking corticosteroids only also showed
an increase in the mean lumbar spine Z-score (from -1.71 to -
1.44 (P = 0.30). This increase could have been caused artificially
by scoliosis. In another study, 16 boys taking alendronate over
two years maintained a mean lumbar spine Z-score of less than -
1 (Hawker 2005). Each boy was taking deflazacort and bone pro-
tection (calcium and vitamin D supplements). Improvements in
spinal Z-scores were significantly associated with starting bisphos-
phonates at a younger age (P = 0.01). In both of the above studies
a mild gastrointestinal side-effect was the major complaint associ-
ated with alendronate.
A retrospective study examined 52 childrenwithDMDtaking oral
risedronate treatment (treated) for a mean duration of 3.6 years
while taking long-term corticosteroids (Srinivasan 2016). The in-
vestigators also collected data from a historical comparison group
of children with DMD who took corticosteroids alone (N = 15).
Risedronate-treated children also received vitamin D supplemen-
tation of 800 IU/day to 1000 IU/day; it is not clear if the untreated
children also received vitamin D. Risedronate was stopped in 9/
52 children due to side-effects (abdominal pain, vomiting, consti-
pation, joint pain, flu-like symptoms, and dizziness). DXA results
were available in 35 children who continued risedronate treatment
for over 12 months. The treated group DXA scores remained sta-
ble (mean 0.04 (standard deviation (SD) 1.3) at baseline and -
0.04 (1.2) at final assessment, mean follow-up: 4.9 years). The
untreated group mean (SD)-adjusted Z-score decreased from -0.1
(1.3) to -1.00 (1.3) (mean follow-up: 6.2 years). During this study,
three ’treated’ children, all with baseline Z-scores of less than -1
developed lumbar vertebral fractures. This study did not assess the
presence of asymptomatic vertebral fractures. Given that it was
not clear if the untreated group received vitamin D, it is unclear
whether or not the improvement in bone mineral density was due
to risedronate or vitamin D or a combination of both. Although
no child experienced osteonecrosis of the jaw, a significant pro-
portion of participants stopped taking risedronate because of side-
effects.
Sbrocchi 2012 retrospectively studied intravenous bisphosphonate
(pamidronate or zoledronic acid) treatment for painful vertebral
fractures in boys with DMD. At baseline, there were 27 vertebral
fractures among the seven boys. After two years of bisphospho-
nate treatment, 17 of the fractures showed an improved vertebral
height ratio, 10 vertebrae were stabilised, and no vertebrae showed
a reduced vertebral height ratio. Treatment did not prevent the
development of new vertebral fractures in some participants, but it
did remove the associated back pain completely in three boys and
improved back pain in the remaining four. The median change in
lumbar spine bone mineral density Z-score was 0.5 SD (interquar-
tile range: -0.3 to 1.7). Side-effects occurred mostly with the first
dose of intravenous bisphosphonate treatment.
From the non-randomised studies available, bisphosphonate treat-
ment may stabilise bone mineral density. It is not clear if bispho-
sphonates prevent fragility fractures from the data available. The
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effect of bisphosphonates may well depend upon the time they are
started in relation to bone fragility appearing.
Vitamin D and calcium
A prospective study inDMD involving 33 participants taking cor-
ticosteroids for three years reported that 67% (22 of 33) had an
increase in bone mineral density in response to vitamin D (cal-
cifediol and 25-dihydroxyvitamin D (25OHD)) and increased
dietary calcium (Bianchi 2011). During the first year of the study,
participants had increased dietary calcium but no additional vi-
tamin D, and the bone mineral density decreased at the lumbar
spine in all participants, withmeasured urinary calcium and serum
25OHD levels below normal. In 20 participants, serum 25OHD
levels were below 20 ng/ml. During the following years, partici-
pants took calcifediol (0.8 mcg/kg/day) and increased dietary cal-
cium (11,236 mg/day, P < 0.001). The bone mineral density at
the spine significantly increased in 22 participants, urinary cal-
cium increased to normal levels, and serum calcium and 25OHD
returned to normal levels. No vertebral fractures occurred during
the three-year study, but seven fractures of the leg and foot oc-
curred: four in the non-treatment year and three in the following
treatment years. The overall increase in both lumbar spine and
total body bone mineral density were not thought to be associated
with an increase in body (bone) size and pubertal development, as
most participants were prepubertal.
Weight-bearing exercise
Six participants with DMD (median age: 6.8 years) walking with-
out assistance and taking corticosteroids had whole-body vibra-
tion therapy two or three times a week for 10 weeks and were
assessed for one year (Söderpalm 2013). No significant changes
occurred in bone mineral density in total body, spine, hip, or heel
bone or bone markers after the intervention treatment period. No
fractures occurred before or during the study. This was a very small
observational study with no controls; hence, we could draw no
clinical conclusions.
Overall completeness and applicability of
evidence
Limited reports from two small studies are only available in pub-
lished conference proceedings at this time. There is as yet no fully
published evidence from randomised trials.
Vitamin D, calcium, and testosterone
We identified no randomised or controlled trials to assess vitamin
D, calcium, and testosterone treatment for corticosteroid-induced
osteoporosis and fragility fractures in DMD.
Quality of the evidence
We cannot fully assess the quality of the studies from the abstract
publications. The two included studies met prespecified eligibility
criteria and had small sample sizes (N = 13 and N = 21). Both tri-
als reported that they randomised participants to an intervention
group or no intervention or placebo group. The low-magnitude,
high-frequency vibration study reported blinding (Bianchi 2013),
but this was unclear in the bisphosphonate study (McSweeney
2014). From the McSweeney 2014 abstract, it was unclear if par-
ticipants in the intervention group were taking corticosteroids or
not.
Of the excluded studies, four were retrospective cohort studies
or uncontrolled studies with a small sample size (Biggar 2004;
Cohran 2008; Hawker 2005; Srinivasan 2016). These studies had
many limitations and provided very low quality evidence.
Potential biases in the review process
There were few limitations to this process. The small randomised
controlled trials performed in DMD are unlikely to capture and
provide high-quality adverse event data, especially for rare events.
The comprehensive searches were updated throughout the review
process when necessary.
Agreements and disagreements with other
studies or reviews
We examined published systematic reviews that analysed interven-
tions to prevent corticosteroid-induced osteoporosis and fragility
fractures in other conditions.
Bisphosphonates
Reviews of treatments for corticosteroid-induced osteoporosis in
cystic fibrosis, neuromuscular disease, and chronic illnesses found
extensive variation in the choice of bisphosphonate, dosing regi-
men, and outcome measurement (Conwell 2014; Ward 2007b).
Bisphosphonates had a positive effect on the lumbar spine bone
mineral density, especially in the short term, although there was
some heterogeneity.
The trials reviewed, Conwell 2014 and Ward 2011, reported no
new fractures in treatment groups over a two-year period.
In Ward 2007b, although bisphosphonates were well tolerated,
the major complaint was bone pain in those taking bisphospho-
nates but not taking corticosteroids (odds ratio (OR) 18.52, 95%
confidence interval (CI) 5.39 to 63.57, six trials). This effect was
mostly related to intravenous bisphosphonates (OR 14.17, 95%
CI 3.64 to 55.17) and oral risedronate (OR 43.59, 95% CI 2.27
to 837.56). Conwell 2014 listed gastrointestinal effects as a major
side-effect.
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Overall, both reviews found insufficient evidence to justify the
routine use of the bisphosphonates in clinical care to prevent or
treat corticosteroid-induced osteoporosis and fractures (Conwell
2014;Ward 2007b). The included trials were too short tomonitor
vertebral fracture events and treatment adequately.
Vitamin D
Participants with cystic fibrosis taking vitamin D supplements
had significantly higher serum levels (mean difference (MD) 7.24
ng/ml, 95% confidence interval 5.01 to 9.46 ng/ml) than those
taking a placebo (Ferguson 2014). Vitamin D supplementation
was found not to improve bone density in healthy children with
normal vitamin D levels, but was found to be clinically useful in
children with low serum vitamin D levels by preventing bone loss
at the lumbar spine (Homik 1998; Winzenberg 2010).
The vitamin D Individual Patient Analysis of Randomized Trials
showed that vitamin D given alone was not effective in preventing
fractures (risk ratio (RR) 0.92, 95% CI 0.86 to 0.99, P = 0.025),
but if taken with calcium, the combination reduced the risk of
vertebral fragility fractures (DIPART 2010). Evidence from ran-
domised and cross-over design trials and meta-analysis supports
the use of calcium in combination with vitamin D as a preventive
treatment for bone loss in the spine of people treated with cor-
ticosteroids and adults over 50 years of age (Amin 1999; Homik
1998; Rianthavorn 2012; Tang 2007; Warady 1994). Further re-
search is required to investigate the effect of vitamin D levels on
bone strength of patients with DMD (Wong 2010).
Weight-bearing exercise
No useful data were available from studies of weight-bear-
ing exercise in people over 40 with vertebral fragility fractures
(Papaioannou 2003). A systematic review of vibration treatment
for osteoporosis is published only as a protocol (Lorenzen 2010).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
We know of no evidence from high-quality randomised controlled
trials (RCTs) about the efficacy of interventions to prevent or
treat corticosteroid-induced osteoporosis and prevent osteoporotic
fragility fractures in DMD in children and adults, other than lim-
ited results from two trials reported in abstracts. There is no evi-
dence of harm, but formal trial reports are awaited. Findings from
two ongoing relevant studies and the two trials for which only
abstracts are available will be important in future updates of this
review.
Implications for research
There is a need for good-quality RCTs of treatments for bone
protection and treatment of corticosteroid-induced osteoporosis
in Duchenne muscular dystrophy (DMD).
When fully published, the included and ongoing studies of bis-
phosphonates and weight-bearing activity will be important con-
tributors to this review. Nevertheless, future RCT design and de-
livery needs to ensure the following:
• employment of an adequate sample size;
• that the clinical indications for starting interventions are
addressed;
• that dose, duration, and type of intervention (treatment
strategies) are addressed;
• employment of outcomes in addition to bone density Z-
scores relevant to children or adolescents, including the number
of vertebral fractures, with a clear definition of type of fracture.
Pain and quality of life should be also assessed during the trial
period and measured using validated scales; and
• assessment of children, adolescents, and adults with DMD
or those who are ambulant and non-ambulant separately, as
appropriate.
In this group of patients itmay not be ethical towithhold treatment
or give a placebo, so comparisons could be made to routine care,
alternative interventions, or between different treatment groups. It
is important that the RCTs consider that age, weight, duration of
corticosteroid therapy, mobility, weight-bearing activity, delayed
puberty, and growth therapy will affect the outcome measures.
Patient groups (children, adolescents, and adults) could be either
assessed in separately designed trials, or results could be analysed
separately per group to reflect these factors.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Bianchi 2013
Methods Prospective, double-blind, randomised, placebo-controlled study
Participants Ambulant children with DMD (N = 21) (mean age: 9.3 ± 3.9 years)
Interventions For at least 6 months before the study, all children were treated with corticosteroids
and calcifediol (0.7 mcg/kg/day) and took 100% of the calcium recommended daily
allowance
Randomised intervention: weight-bearing activity (low-magnitude high-frequency vi-
bration (delivering 0.3 g, 30 Hz; N = 11)) or placebo devices (N = 10) for 10 minutes
per day for 1 year
Outcomes • Bone mineral density (by dual-energy X-ray absorptiometry) at spine, hip, and
total body less head
• Laboratory tests: calcium, 25-hydroxyvitamin D, and bone turnover markers
Funding sources Not stated - the abstract did not provide information on funding sources
Declarations of interest Not stated
Notes The full trial is not yet published. The conference abstract was published in 2013, but
a trial start date and end date has not been provided. An email response from Bianchi
2013 confirmed that there was as yet no more published information
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk This was a prospective, double-blind, ran-
domised, placebo-controlled study
Allocation concealment (selection bias) Unclear risk The study was reported as an abstract only.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk This was a double-blind, randomised,
placebo-controlled study
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk This was a double-blind, randomised,
placebo-controlled study
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The study was reported as an abstract only.
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Bianchi 2013 (Continued)
Selective reporting (reporting bias) Unclear risk The study was reported as an abstract only.
Other bias Unclear risk The study was reported as an abstract only.
McSweeney 2014
Methods Randomised controlled trial
Participants Boys (N = 13) affected with DMD (median age (years): 8.5, range: 5.4 to 15.5) and
spine Z-score ≤ 1.0
Interventions Risedronate group: risedronate 1 mg/kg per week (maximum 35 mg), calcium (500 mg/
day), and vitamin D (10 mg/day) (N = 6)
Control group: calcium and vitamin D (N = 7)
9 participants were ambulant and on corticosteroid therapy.
The effects were determined after 1 year of treatment with risedronate. There was not
enough detail in the abstract on timing of risedronate treatment with reference to taking
steroids
Outcomes • Effects on bone mineral density Z-score
Funding sources Not stated - the abstract did not provide information on funding sources
Declarations of interest Not stated
Notes The full trial is not published. A conference abstract was published in 2014. The trial start
date was 22 June 2010 with no end date provided. EudraCT Number: 2009-017649-
67
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Eligible participants (spine Z-score less than -1.0) were
randomised to each treatment arm
Allocation concealment (selection bias) Unclear risk The study was reported as an abstract only.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk The study was reported as an abstract only.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk The study was reported as an abstract only.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The study was reported as an abstract only.
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McSweeney 2014 (Continued)
Selective reporting (reporting bias) Unclear risk The study was reported as an abstract only.
Other bias Unclear risk The study was reported as an abstract only.
DMD: Duchenne muscular dystrophy.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Adachi 2001 This study did not include participants with DMD.
Bianchi 2011 This study was not a RCT.
Biggar 2004 This study was not a RCT. The author confirmed this.
Cohran 2008 This study was not a RCT.
Cohran 2013 This study did not include participants with DMD.
Dubowitz 1984 This controlled study did not assess the effect of exercise on bone health
Hawker 2005 This study was a before and after trial, not a RCT.
Houston 2014 This was a retrospective cohort study, not a RCT.
Mayo 2012 This was a prospective observational study, not a RCT.
Sbrocchi 2012 This study was not a RCT.
Scott 1981 This controlled study did not assess the effect of exercise on bone health
Srinivasan 2016 This was a retrospective cohort study, not a RCT.
Söderpalm 2013 This study was not a RCT.
Yilmaz 2004 This study did not assess the effect of the intervention on bone health
DMD: Duchenne muscular dystrophy.
RCT: randomised controlled trial.
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Characteristics of ongoing studies [ordered by study ID]
ACTRN12610000507088
Trial name or title Clinical trial of zoledronic acid in children and adolescents with Duchenne muscular dystrophy
Methods Open-label RCT
Participants Children and adolescents with DMD
Interventions Zoledronic acid (Aclasta) versus vitamin D plus calcium
Outcomes • Change in lumbar spine bone density over 12 months
Starting date 1 September 2010 for the 1st recruited participant
Contact information email: margaret.zacharin@rch.org.au
Notes The trial start date was 13 September 2013, and the estimated final collection date was 31 December 2015.
Trial ID number: ACTRN12610000507088
No further information was published.
Source of monetary support: Altum Novartis
NCT01954940
Trial name or title Whole body vibration therapy in boys with Duchenne muscular dystrophy
Methods RCT, parallel assignment, open-label interventional
Participants Boys with DMD
Interventions Whole-body vibration therapy
Outcomes Primary outcome measures:
• Safety of whole-body vibration therapy
• Gain in muscle strength and prolongation of ambulation from baseline to 8 weeks of therapy
Secondary outcome measures:
• A change in muscle strength
• Any muscle function change
• Any measurable change in muscle endurance
• Quality of life changes
• Gait changes
• Bone health
Starting date March 2014
Contact information Hugh McMillan, MD hmcmillan@cheo.on.ca
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NCT01954940 (Continued)
Notes The trial start date was stated as 13 September 2013, with an estimated final collection date of March 2015.
Trial ID number: NCT01954940
No further information, including details of funding, was published
DMD: Duchenne muscular dystrophy.
RCT: randomised controlled trial.
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D A T A A N D A N A L Y S E S
This review has no analyses.
A D D I T I O N A L T A B L E S
Table 1. Spine and whole-body Z-scores (McSweeney 2014)
Risedronate (plus calcium and vitamin D
supplementation)
Control (calciumand vitaminD supplementation alone)
Baseline 12-month Baseline 12 months
Median spine Z-score
(range)
-1.75 (-1.2 to -3.5) -0.8 (-1.7 to 0) -2.2 (-4.1 to -1.2) -1.6 (-8.4 to -0.8)
Median whole-body Z-
score (range)
-1.95 (-0.5 to 2.7)* 1.3 (-1.0 to 2.5) -1.2 (-1.6 to 4.7) -0.8 (-3.1 to 3)
A median of -1.95 is outside the range given, but we were unable to confirm correct figures with the study author.
A P P E N D I C E S
Appendix 1. Cochrane Neuromuscular Specialised Register (CRS) search strategy
#1 muscular NEAR5 dystroph* [REFERENCE] [STANDARD]
#2 duchenne or dystrophinopathy [REFERENCE] [STANDARD]
#3 nonambula* or “non ambula*” [REFERENCE] [STANDARD]
#4 #1 or #2 or #3 [REFERENCE] [STANDARD]
#5 “vertebral deformity” or fracture or compression or crush or wedging or biconcavity [REFERENCE] [STANDARD]
#6 osteoporosis [REFERENCE] [STANDARD]
#7 bone or bmc [REFERENCE] [STANDARD]
#8 (bone or bmc):so [REFERENCE] [STANDARD]
#9 #7 not #8 [REFERENCE] [STANDARD]
#10 lumbar or spine [REFERENCE] [STANDARD]
#11 MeSH DESCRIPTOR Diphosphonates Explode All [REFERENCE] [STANDARD]
#12 bisphosphonate* or diphosphonate* [REFERENCE] [STANDARD]
#13 alendronate or clodronate or etidronate or ibandronate or incadronate or opadronate or pamidronate or risedronate or tiludronate
or zoledronate [REFERENCE] [STANDARD]
#14 calcitonin or calcium or calcitriol or cholecalciferol* or Ergocalciferol* [REFERENCE] [STANDARD]
#15 “vitamin D” [REFERENCE] [STANDARD]
#16 “dietary supplements” or testosterone [REFERENCE] [STANDARD]
#17 Teriparatide or “weight bearing” or diet or exercise [REFERENCE] [STANDARD]
#18 “non drug” NEXT therapy [REFERENCE] [STANDARD]
#19 #5 or #6 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17
or #18 [REFERENCE] [STANDARD]
#20 #4 and #19 [REFERENCE] [STANDARD]
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#21 (#4 and #19) AND (INREGISTER) [REFERENCE] [STANDARD]
Appendix 2. CENTRAL search strategy
Search run on Mon Sep 12 2016
#1(muscular near dystrophy or duchenne near dystrophy or dystrophinopathy or non next ambula* or nonambula*):TI,AB,KY520
#2(“vertebral deformity” or fracture or compression or crush or wedging or biconcavity):TI,AB,KY11862
#3(steroid near1 induced and osteoporosis):TI,AB,KY34
#4(steroid near1 induced and “bone loss”):TI,AB,KY18
#5(steroid near1 induced and osteopenia):TI,AB,KY6
#6MESH DESCRIPTOR Osteoporosis WITH QUALIFIERS CI205
#7(secondary next osteoporosis):TI,AB,KY41
#8(bone next strength):TI,AB,KY248
#9(bone next fragil*):TI,AB,KY51
#10(bone next loss):TI,AB,KY2938
#11(“bone density” or “bone mineral density” or “bone mineral content” or bmc):TI,AB,KY7029
#12(bone next deformity or lumbar next spine):TI,AB,KY3340
#13MESH DESCRIPTOR Spine EXPLODE ALL TREES3740
#14MESH DESCRIPTOR Diphosphonates EXPLODE ALL TREES2659
#15(bisphosphonate* or diphosphonate*):TI,AB,KY1765
#16(alendronate or clodronate or etidronate or ibandronate or incadronate or opadronate or pamidronate or risedronate or tiludronate
or zoledronate):TI,AB,KY2255
#17(calcitonin or calcium or calcitriol or ergocalciferol* or “vitamin D”):TI,AB,KY23566
#18MESH DESCRIPTOR Calcifediol EXPLODE ALL TREES215
#19(“dietary supplements” or teriparatide):TI,AB,KY7410
#20(“non drug” next therapy):TI,AB,KY16
#21(diet or exercise or “weight bearing” or testosterone):TI,AB,KY79090
#22#2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #
21119677
#23#1 and #22119
#24sr-neuromusc:cc5974
#25#23 not #2478
Appendix 3. MEDLINE (OvidSP) search strategy
Ovid MEDLINE(R) 1946 to August Week 5 2016
Database: Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R)
<1946 to Present>
Search Strategy:
--------------------------------------------------------------------------------
1 randomized controlled trial.pt. (430785)
2 controlled clinical trial.pt. (91698)
3 randomized.ab. (370085)
4 placebo.ab. (178870)
5 drug therapy.fs. (1906928)
6 randomly.ab. (263462)
7 trial.ab. (384951)
8 groups.ab. (1638648)
9 or/1-8 (3900462)
10 exp animals/ not humans.sh. (4315089)
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11 9 not 10 (3364542)
12 exp muscular dystrophy/ (23751)
13 ((muscular adj5 dystrophy) or duchenne or dystrophinopathy).tw. (19784)
14 (non ambula* or nonambula*).mp. (1602)
15 or/12-14 (30865)
16 (vertebral deformity or fracture or compression or crush or wedging or biconcavity).mp. (270009)
17 ((steroid adj1 induced) and osteoporosis).tw. (252)
18 ((steroid adj1 induced) and bone loss).tw. (75)
19 ((steroid adj1 induced) and osteopenia).tw. (37)
20 osteoporosis/ci (2760)
21 secondary osteoporosis.tw. (744)
22 (bone adj1 strength).tw. (4188)
23 (bone adj1 fragil$).tw. (1680)
24 (bone adj1 loss).tw. (23360)
25 (bone mineral density or bone mineral content or bmc).mp. (38924)
26 Bone Density/ (45641)
27 (bone adj1 deformity).tw. (313)
28 (lumbar adj1 spine).tw. (24195)
29 Lumbar Vertebrae/ (44335)
30 exp Spine/ (125272)
31 exp Diphosphonates/ (22891)
32 (bisphosphonate$ or diphosphonate$).tw. (17118)
33 (alendronate or clodronate or etidronate or ibandronate or incadronate or opadronate or pamidronate or risedronate or tiludronate
or zoledronate).tw. (9832)
34 Calcitonin/ (14866)
35 calcium/ (253994)
36 Calcitriol/ (13310)
37 exp Cholecalciferol/ (24172)
38 Ergocalciferols/ (2943)
39 Vitamin D/ (27463)
40 Dietary Supplements/ (41269)
41 Teriparatide/ (1589)
42 Weight-Bearing/ (17139)
43 (non-drug adj1 therapy).tw. (103)
44 (diet or exercise).tw. (454348)
45 exp Testosterone/ (65868)
46 testosterone.mp. (91168)
47 or/16-46 (1299956)
48 11 and 15 and 47 (319)
49 remove duplicates from 48 (303)
Appendix 4. Embase (OvidSP) search strategy
Database: Embase <1980 to 2016 Week 37>
Search Strategy:
--------------------------------------------------------------------------------
1 crossover-procedure.sh. (48595)
2 double-blind procedure.sh. (131481)
3 single-blind procedure.sh. (23071)
4 randomized controlled trial.sh. (416900)
5 (random$ or crossover$ or cross over$ or placebo$ or (doubl$ adj blind$) or allocat$).tw,ot. (1294764)
6 trial.ti. (207191)
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7 or/1-6 (1447525)
8 exp animal/ or exp invertebrate/ or animal.hw. or non human/ or nonhuman/ (23158822)
9 human/ or human cell/ or human tissue/ or normal human/ (17529785)
10 8 not 9 (5661779)
11 7 not 10 (1276235)
12 limit 11 to embase (1041572)
13 exp muscular dystrophy/ (36206)
14 ((muscular adj5 dystrophy) or duchenne or dystrophinopathy).tw. (23473)
15 (non ambula* or nonambula*).mp. (2209)
16 or/13-15 (41054)
17 vertebra malformation/ (2625)
18 (vertebral deformity or fracture or compression or crush or wedging or biconcavity).mp. (420882)
19 corticosteroid induced osteoporosis/ (1750)
20 ((steroid adj1 induced) and osteoporosis).tw. (356)
21 ((steroid adj1 induced) and bone loss).tw. (104)
22 ((steroid adj1 induced) and osteopenia).tw. (52)
23 osteoporosis/pc [Prevention] (9654)
24 secondary osteoporosis.tw. (1320)
25 (bone adj1 strength).tw. (5666)
26 (bone adj1 fragil$).tw. (2437)
27 (bone adj1 loss).tw. (27779)
28 (bone mineral density or bone mineral content or bmc).mp. (52199)
29 bone density/ (70004)
30 bone malformation/ (4902)
31 (((bone adj1 density) or bone) adj1 deformity).tw. (404)
32 exp spine/ (149050)
33 (lumbar vertebra$ or lumbar spine).tw. (39235)
34 bisphosphonic acid derivative/ (28745)
35 (bisphosphonate$ or diphosphonate$).tw. (23178)
36 (alendronate or clodronate or etidronate or ibandronate or incadronate or opadronate or pamidronate or risedronate or tiludronate
or zoledronate).tw. (13945)
37 calcitonin/ (21362)
38 calcium/ (242503)
39 calcitriol/ (25813)
40 colecalciferol/ (14523)
41 ergocalciferol/ (6751)
42 vitamin D/ (59328)
43 diet supplementation/ (75411)
44 “parathyroid hormone[1-34]”/ (5412)
45 resistance training/ (9634)
46 weight bearing.mp. (29389)
47 (non-drug adj1 therapy).tw. (166)
48 (diet or exercise).tw. (550445)
49 testosterone.mp. (114818)
50 or/17-49 (1607048)
51 12 and 16 and 50 (162)
52 remove duplicates from 51 (159)
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Appendix 5. CINAHL Plus (EBSCOhost) search strategy
Monday, September 12, 2016 9:27:36 AM
S48 S46 AND S47 5
S47 EM 20150601- 413,167
S46 s45 Limiters - Exclude MEDLINE records
Search modes - Boolean/Phrase 22
S45 S18 AND S19 AND S44 199
S44 S20 or S21 or S22 or S23 or S24 or S25 or S26 or S27 or S28 or S29 or S30 or S31 or S32 or S33 or S34 or S35 or S36 or S37
or S38 or S39 or S40 or S41 or S42 or S43 334,135
S43 diet or exercise or testosterone replacement therapy 197,974
S42 “non drug” W1 therapy 37
S41 weight W1 bearing 6,645
S40 teriparatide 392
S39 vitamin W1 D 15,233
S38 Cholecalciferol* or Ergocalciferol* 886
S37 calcitonin or calcium or calcitriol 29,703
S36 alendronate or clodronate or etidronate or ibandronate or incadronate or opadronate or pamidronate or risedronate or tiludronate
or zoledronate 2,128
S35 bisphosphonate* or diphosphonate* 6,770
S34 (MH “Diphosphonates+”) 6,762
S33 spine 24,224
S32 lumbar N4 vertebrae 10,854
S31 bone N4 deformity OR lumbar spine 4,994
S30 bone density 14,412
S29 bone mineral density or bone mineral content or bmc 6,242
S28 bone loss 4,602
S27 bone fragil* 260
S26 bone strength 1,008
S25 secondary osteoporosis 203
S24 (MH “Osteoporosis/CI”) 576
S23 steroid W1 induced AND osteopenia 2
S22 steroid W1 induced AND bone loss 8
S21 steroid W1 induced AND osteoporosis 32
S20 vertebral W1 deformity OR ( fracture or compression or crush or wedging or biconcavity ) 67,110
S19 muscular W5 dystrophy OR ( duchenne or dystrophinopathy or “non ambula*” or nonambula*) 3,104
S18 S1 or S2 or S3 or S4 or S5 or S6 or S7 or S8 or S9 or S10 or S11 or S12 or S13 or S14 or S15 or S16 or S17 855,321
S17 ABAB design* 92
S16 TI random* or AB random* 178,868
S15 ( TI (cross?over or placebo* or control* or factorial or sham? or dummy) ) or ( AB (cross?over or placebo* or control* or factorial
or sham? or dummy) ) 355,248
S14 ( TI (clin* or intervention* or compar* or experiment* or preventive or therapeutic) or AB (clin* or intervention* or compar* or
experiment* or preventive or therapeutic) ) and ( TI (trial*) or AB (trial*) ) 129,453
S13 ( TI (meta?analys* or systematic review*) ) or ( AB (meta?analys* or systematic review*) ) 48,376
S12 ( TI (single* or doubl* or tripl* or trebl*) or AB (single* or doubl* or tripl* or trebl*) ) and ( TI (blind* or mask*) or AB (blind*
or mask*) ) 27,566
S11 PT (“clinical trial” or “systematic review”) 131,822
S10 (MH “Factorial Design”) 977
S9 (MH “Concurrent Prospective Studies”) or (MH “Prospective Studies”) 288,464
S8 (MH “Meta Analysis”) 25,156
S7 (MH “Solomon Four-Group Design”) or (MH “Static Group Comparison”) 49
S6 (MH “Quasi-Experimental Studies”) 7,981
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S5 (MH “Placebos”) 9,796
S4 (MH “Double-Blind Studies”) or (MH “Triple-Blind Studies”) 33,944
S3 (MH “Clinical Trials+”) 202,467
S2 (MH “Crossover Design”) 13,928
S1 (MH“RandomAssignment”) or (MH“RandomSample”) or (MH“Simple RandomSample”) or (MH“StratifiedRandom Sample”)
or (MH “Systematic Random Sample”) 73,492
Appendix 6. Web of Science Core Collection - Indexes=CPCI-S Timespan=1900-2016
2001-2016
#19 #17 AND #16
Refined by: DOCUMENT TYPES: (PROCEEDINGS PAPER OR MEETING ABSTRACT)
DocType=All document types; Language=All languages;
#18 #17 AND #16
#17 TS=(random* or “clinical trial” or group or groups or blind* or crossover or “crossover” or “controlled trial”)
#16 #15 AND #1
#15 #14 OR #13 OR #12 OR #11 OR #10 OR #9 OR #8 OR #7 OR #6 OR #5 OR #4 OR #3 OR #2
#14 TS=(bisphosphonate* or diphosphonate* or alendronate or clodronate or etidronate or ibandronate or incadronate or opadronate
or pamidronate or risedronate or tiludronate or zoledronate or calcitonin or calcium or calcitriol or cholecalciferol* or Ergocalciferol*
or “vitamin D” or “dietary supplements” or Teriparatide or “weight bearing” or diet or exercise or (“non drug” NEAR therapy) or bone
or testosterone)
#13 TS=((bone NEAR/3 deformity) or (lumbar NEAR/3 spine))
#12 TS=(“bone density” or “lumbar vertebra*”)
#11 TS=(“bone mineral density” or “bone mineral content” or bmc)
#10 TS=(“bone loss”)
#9 TS=(bond NEAR/3 fragil*)
#8 TS=(bone NEAR/3 strength)
#7 ts=(“secondary osteoporosis”)
#6 TS=(induced and osteopenia)
#5 TS=(induced and “bone loss”)
#4 TS=(induced and osteoporosis)
#3 TOPIC: (fracture or compression or crush or wedging or biconcavity or lumbar or spine)
#2 TOPIC: (“vertebral deformity” or fracture or compression or crush or wedging or biconcavity or “vertebral deformity”)
#1 TOPIC: ((muscular NEAR/5 dystroph*) or duchenne or dystrinopathy or nonambula* or “non ambula*”)
Appendix 7. clinicaltrials.gov search strategy
Search performed 11 October 2016
Duchenne muscular dystrophy AND (bone OR bone mineral density OR fractures) AND (vitamin D OR calcium OR testosterone
OR physical activity OR exercise)
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Appendix 8. apps.who.int/trialsearch/ search strategy
Search performed 11 October 2016.
The following terms were used:
Duchenne muscular dystrophy AND bone 8
Duchenne muscular dystrophy AND osteoporosis 1
Duchenne muscular dystrophy AND bisphosphonates 1
Duchenne muscular dystrophy AND vitamin D 2
Duchenne muscular dystrophy AND calcium 3
Duchenne muscular dystrophy AND testosterone 1
Duchenne muscular dystrophy AND whole body vibration 1
Appendix 9. www.isrctn.com search strategy
Search performed 11 October 2016
Duchenne muscular dystrophy
Appendix 10. Additional methods described in the protocol
Data extraction and management
Two review authors (JMB and MS) will independently extract data using a standard data extraction form. One author (JMB) will enter
data into the Cochrane software Review Manager 5 (RevMan) (RevMan 2014), and a second author (MS) will check data entry. JMB
will contact study authors directly for any additional or missing data required. We will note in the ’Characteristics of included studies’
table if outcome data are not reported in a usable way.
Where studies provide data on our outcomes at time points less than or more than 24 months, we will extrapolate the data to 24
months when it is reasonable to do so. We will assume a linear response rate but carry out a sensitivity analysis to assess the effects of
the imputation, by re-analysis using alternative imputed values.
Measures of treatment effect
Statistical methods used to measure treatment effects will be in accordance with theCochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011a).
We will analyse dichotomous data as risk ratios (RR) and continuous data as mean difference, or standardised mean difference for
results across studies with outcomes that are conceptually the same but measured in different ways. We will report these measures of
effect with 95% confidence intervals (CI).
Wewill undertakemeta-analyses, usingRevMan, only where this ismeaningful, that is, if the treatments, participants, and the underlying
clinical question are similar enough for pooling to make sense.
Unit of analysis issues
Where a single trial includes multiple trial arms, we will include only the relevant arms. If we combine two comparisons (e.g. drug A
versus placebo and drug B versus placebo) in the same meta-analysis, we will halve the control group to avoid double-counting. For
each participant, there may be multiple observations for the same outcome.
Dealing with missing data
We will attempt to contact the trial correspondence author to obtain any missing data. If we are unable to obtain data, we will try to
find out why the data are missing and decide, based on whether they are missing at random or not, whether to analyse available data or
impute missing values using a statistical model. We will consider how best to include missing data where baseline-observation-carried-
forward (BOCF) or last-observation-carried-forward (LOCF) methods have been used for imputation and attempt to standardise these
between studies (LOCF being preferable).
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Wewill address the potential implications of missing data (for example, loss to follow -up and no outcome obtained, lack of compliance)
in the ’Discussion’.
Assessment of heterogeneity
We will assess clinical heterogeneity by judging, qualitatively, the differences between studies regarding the participants, therapies, and
reporting of important study outcomes.
We will statistically test heterogeneity of intervention effects among trials using the standard Chi² statistic (P value) and the Higgins
I² statistic expressed as a percentage. We will take P values of less than 0.05 as evidence of heterogeneity. We will interpret I² for
heterogeneity as follows:
• 0% to 40%: may not be important;
• 30% to 60%: may represent moderate heterogeneity;
• 50% to 90%: may represent substantial heterogeneity; and
• 75% to 100%: considerable heterogeneity.
If we identify substantial unexplained heterogeneity, we will report it and explore possible causes by prespecified subgroup analysis
(Higgins 2011b).
Assessment of reporting biases
To detect the presence of publication bias, we will construct a funnel plot using RevMan if there are a reasonable number of studies (at
least 10 in the same meta-analysis). We will use Beggs’s and Egger’s tests to verify the bias (Begg 1994; Egger 1997).
Data synthesis
If there is no substantial or considerable heterogeneity, we will synthesise the data in a meta-analysis using RevMan. We will perform
both fixed-effect and random-effects models for comparison purposes and use the most appropriate, depending upon the degree of
heterogeneity.
If the review includes more than one comparison, and we cannot include them in the same analysis, we will report the results for each
comparison separately.
Cost-utility analyses
We will consider cost-effectiveness of interventions per QALY (quality-adjusted-life-year) in the Discussion, where data are available.
Subgroup analysis and investigation of heterogeneity
If there are sufficient data, we plan to undertake the following subgroup analyses using the outcome vertebral fractures:
1. ambulant versus non-ambulant (due to disease progression, these groups will reflect age groups); and
2. intervention versus intervention combination.
Within each group, we will use the I² statistic for heterogeneity, and if its value is greater than 50%, we will scrutinise the trials and
forest plots for differences to explain the heterogeneity. If we find no explanation, we will repeat the analysis using a random-effects
model.
’Summary of findings’ table
We will create a ’Summary of findings’ table using the following outcomes:
• change in bone mineral density as assessed by Z-score;
• frequency of vertebral fragility fractures; and
• adverse events.
We will use the five GRADE considerations (study limitations, consistency of effect, imprecision, indirectness, and publication bias)
to assess the quality of a body of evidence (studies that contribute data for the prespecified outcomes). We will use methods and
recommendations described in Section 8.5 and Chapter 12 of the Cochrane Handbook for Systematic Reviews of Interventions, Higgins
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2011a, using GRADEpro software. We will justify all decisions to downgrade or upgrade the quality of studies using footnotes, and
we will make comments to aid readers’ understanding of the review where necessary.
Sensitivity analysis
We will perform a sensitivity analysis to determine whether conclusions are robust by undertaking both fixed-effect and random-effects
meta-analysis. We will perform sensitivity analyses to assess the effect of including studies at high risk of bias on the change in vertebral
bone mineral density (body height corrected Z-scores), and by repeating the meta-analysis excluding any studies at high risk of bias. If
we have imputed missing data, we will assess the effects of the imputation by re-analysis using several alternative imputed values.
C O N T R I B U T I O N S O F A U T H O R S
Jennifer Bell prepared the protocol with discussion and comments from review authors. Dr Janet Watters reviewed the text from the
perspective of a healthcare consumer as the mother of a boy with Duchenne muscular dystrophy.
Conceiving the review: MS; BB
Co-ordinating the review: JMB
Undertaking manual searches: JMB
Organising retrieval of papers: JMB
Screening retrieved papers against inclusion criteria: JMB; MS
Writing to authors of papers for additional information: JMB
Data management for the review: JMB
Data extraction and quality assessment: JMB; MS
Interpretation of data: JMB; MS; BB
Writing the review: JMB with contributions from all authors
Guarantor for the review (one author): MS
Person responsible for reading and checking the review before submission: JMB and all authors
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• Health Research Board/HSC R&D Division Cochrane Fellowship Award, Ireland.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Lack of data prevented full implementation of our protocol (Bell 2014).
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